TY - JOUR
T1 - Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML)
AU - Pemmaraju, Naveen
AU - Kantarjian, Hagop
AU - Ravandi, Farhad
AU - Nogueras-Gonzalez, Graciela M.
AU - Huang, Xuelin
AU - O'Brien, Susan
AU - Wierda, William
AU - Garcia-Manero, Guillermo
AU - Thomas, Deborah
AU - Pierce, Sherry
AU - Verstovsek, Srdan
AU - Borthakur, Gautam
AU - Cortes, Jorge
N1 - Funding Information:
This research is supported in part by the MD Anderson Cancer Center Support Grant P30 CA016672 .
Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Background Little is known about outcomes of acute myeloid leukemia (AML) in adolescents and young adults (AYA). The purpose of this study is to determine the characteristics and outcomes of AYA AML patients in comparison to older adult patients with AML. Patients and Methods We retrospectively analyzed all AML patients treated at our institution from 1965 to 2009 who were aged 16 to 29 years. Results Among 3922 adult AML patients treated during this period, 432 (11%) were identified as AYA. Median age was 23 years (range, 16-29 years); 73 (17%) patients had core binding factor (CBF)-AML [inversion (16), translocation (8:21)], and 51 (12%) had acute promyelocytic leukemia. Complete remission (CR) rates were 93% for CBF AML, 78% for APL, 77% with diploid karyotype, and 68% for other AML. Univariate analysis demonstrated higher rates of CR, CR duration, and overall survival (OS) in the AYA group compared with older patients. On multivariate analysis, AYA age group was independently associated with improved CR rate and CR duration, with a trend for longer OS (P =.085). Conclusion Outcome of AYA AML patients is overall better than for older adults with AML. Despite improvements in treatments and outcomes over time, there is still need for improvement in AYA with AML particularly for those with AML other than CBF and APL.
AB - Background Little is known about outcomes of acute myeloid leukemia (AML) in adolescents and young adults (AYA). The purpose of this study is to determine the characteristics and outcomes of AYA AML patients in comparison to older adult patients with AML. Patients and Methods We retrospectively analyzed all AML patients treated at our institution from 1965 to 2009 who were aged 16 to 29 years. Results Among 3922 adult AML patients treated during this period, 432 (11%) were identified as AYA. Median age was 23 years (range, 16-29 years); 73 (17%) patients had core binding factor (CBF)-AML [inversion (16), translocation (8:21)], and 51 (12%) had acute promyelocytic leukemia. Complete remission (CR) rates were 93% for CBF AML, 78% for APL, 77% with diploid karyotype, and 68% for other AML. Univariate analysis demonstrated higher rates of CR, CR duration, and overall survival (OS) in the AYA group compared with older patients. On multivariate analysis, AYA age group was independently associated with improved CR rate and CR duration, with a trend for longer OS (P =.085). Conclusion Outcome of AYA AML patients is overall better than for older adults with AML. Despite improvements in treatments and outcomes over time, there is still need for improvement in AYA with AML particularly for those with AML other than CBF and APL.
KW - Adherence
KW - Diploid cytogenetics
KW - FLT3 mutation
KW - Older adult
KW - Pediatric
UR - http://www.scopus.com/inward/record.url?scp=84961782241&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961782241&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2015.12.010
DO - 10.1016/j.clml.2015.12.010
M3 - Article
C2 - 26838606
AN - SCOPUS:84961782241
SN - 2152-2650
VL - 16
SP - 213-222.e2
JO - Clinical Lymphoma
JF - Clinical Lymphoma
IS - 4
ER -
